More than 50 long-term effects of COVID-19: a systematic review and meta-analysis

Sandra Lopez-Leon, Talia Wegman-Ostrosky, Carol Perelman, Rosalinda Sepulveda, Paulina A Rebolledo, Angelica Cuapio, Sonia Villapol, Sandra Lopez-Leon, Talia Wegman-Ostrosky, Carol Perelman, Rosalinda Sepulveda, Paulina A Rebolledo, Angelica Cuapio, Sonia Villapol

Abstract

COVID-19 can involve persistence, sequelae, and other medical complications that last weeks to months after initial recovery. This systematic review and meta-analysis aims to identify studies assessing the long-term effects of COVID-19. LitCOVID and Embase were searched to identify articles with original data published before the 1st of January 2021, with a minimum of 100 patients. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. PRISMA guidelines were followed. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included (age 17-87 years). The included studies defined long-COVID as ranging from 14 to 110 days post-viral infection. It was estimated that 80% of the infected patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). Multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.

Conflict of interest statement

The authors are solely responsible for all content, and funders played no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript. S.L.L. is an employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors have no competing interests to declare.

© 2021. The Author(s).

Figures

Figure 1
Figure 1
Study selection. Preferred items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. Out of 15,917 identified studies and after application of the inclusion and exclusion criteria, 15 studies were included in the quantitative synthesis.
Figure 2
Figure 2
Long-term effects of coronavirus disease 2019 (COVID-19). The meta-analysis of the studies included an estimate for one symptom or more reported that 80% of the patients with COVID-19 have long-term symptoms. CRP C-reactive protein, CT computed tomography, IL-6 Interleukin-6, NT-proBNP (NT)-pro hormone BNP, OCD Obsessive Compulsive Disorder, PTSD Post-traumatic stress disorder. This figure was created using Biorender.com.

References

    1. Ritchie, H., Ortiz-Ospina, E., Beltekian, D., Mathieu, E., Hasell, J., Macdonald, B., Giattino, C., Appel, C., Rodés-Guirao, L., & Roser, M. Coronavirus Pandemic (COVID-19). (2021).
    1. Rubin R. As their numbers grow, COVID-19 "long haulers" stump experts. JAMA. 2020;324:1381–1383. doi: 10.1001/jama.2020.17709.
    1. Tenforde MW, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March-June 2020. Morb. Mortal Wkly Rep. 2020;69:993–998. doi: 10.15585/mmwr.mm6930e1.
    1. Townsend L, et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann. Am. Thorac. Soc. 2021 doi: 10.1513/AnnalsATS.202009-1175OC.
    1. Gemelli Against C-P-ACSG. Post-COVID-19 global health strategies: The need for an interdisciplinary approach. Aging Clin. Exp. Res. 2020;32:1613–1620. doi: 10.1007/s40520-020-01616-x.
    1. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.
    1. Chen Q, Allot A, Lu Z. LitCovid: An open database of COVID-19 literature. Nucleic Acids Res. 2021;49:D1534–D1540. doi: 10.1093/nar/gkaa952.
    1. Shamseer L, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ. 2015;350:g7647. doi: 10.1136/bmj.g7647.
    1. Moher D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015;4:1. doi: 10.1186/2046-4053-4-1.
    1. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J. Epidemiol. Community Health. 2013;67:974–978. doi: 10.1136/jech-2013-203104.
    1. Andrews PJ, et al. Olfactory and taste dysfunction among mild-to-moderate symptomatic COVID-19 positive health care workers: An international survey. Laryngosc. Investig. Otolaryngol. 2020;5:1019–1028. doi: 10.1002/lio2.507.
    1. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–605. doi: 10.1001/jama.2020.12603.
    1. Carvalho-Schneider C, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2020 doi: 10.1016/j.cmi.2020.09.052.
    1. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann. Intern. Med. 2020 doi: 10.7326/M20-5661.
    1. Galvan-Tejada CE, et al. Persistence of COVID-19 symptoms after recovery in mexican population. Int. J. Environ. Res. Public Health. 2020 doi: 10.3390/ijerph17249367.
    1. Garrigues E, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4–e6. doi: 10.1016/j.jinf.2020.08.029.
    1. Horvath L, et al. Smell and taste loss in COVID-19 patients: Assessment outcomes in a Victorian population. Acta Otolaryngol. 2020 doi: 10.1080/00016489.2020.1855366.
    1. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int. J. Clin. Pract. 2020 doi: 10.1111/ijcp.13746.
    1. Mandal S, et al. 'Long-COVID': A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020 doi: 10.1136/thoraxjnl-2020-215818.
    1. Munro KJ, Uus K, Almufarrij I, Chaudhuri N, Yioe V. Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. Int. J. Audiol. 2020;59:889–890. doi: 10.1080/14992027.2020.1798519.
    1. Sonnweber T, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: A prospective observational cohort study. Respir. Res. 2020;21:276. doi: 10.1186/s12931-020-01546-2.
    1. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2020 doi: 10.1016/S2215-0366(20)30462-4.
    1. Townsend L, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15:e0240784. doi: 10.1371/journal.pone.0240784.
    1. Xiong Q, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin. Microbiol. Infect. 2021;27:89–95. doi: 10.1016/j.cmi.2020.09.023.
    1. Alwan NA. Track COVID-19 sickness, not just positive tests and deaths. Nature. 2020;584:170. doi: 10.1038/d41586-020-02335-z.
    1. Neufeld KJ, et al. Fatigue symptoms during the first year following ARDS. Chest. 2020;158:999–1007. doi: 10.1016/j.chest.2020.03.059.
    1. Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med. Hypotheses. 2021;146:110469. doi: 10.1016/j.mehy.2020.110469.
    1. Vink M, Vink-Niese A. Could cognitive behavioural therapy be an effective treatment for long COVID and post COVID-19 fatigue syndrome? lessons from the Qure study for Q-fever fatigue syndrome. Healthcare (Basel) 2020 doi: 10.3390/healthcare8040552.
    1. Lamprecht B. Is there a post-COVID syndrome? Pneumologe (Berl) 2020 doi: 10.1007/s10405-020-00347-0.
    1. Pallanti S, Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. J. Psychiatr. Res. 2020;130:215–217. doi: 10.1016/j.jpsychires.2020.08.008.
    1. Nath A. Long-haul COVID. Neurology. 2020;95:559–560. doi: 10.1212/WNL.0000000000010640.
    1. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness Mil. Med. 2015;180:721–723. doi: 10.7205/MILMED-D-15-00085.
    1. Proal A, Marshall T. Myalgic encephalomyelitis/chronic fatigue syndrome in the era of the human microbiome: Persistent pathogens drive chronic symptoms by interfering with host metabolism, gene expression, and immunity. Front. Pediatr. 2018;6:373. doi: 10.3389/fped.2018.00373.
    1. Kingstone T, et al. Finding the ‘right’ GP: A qualitative study of the experiences of people with long-COVID. BJGP Open. 2020 doi: 10.3399/bjgpopen20X101143.
    1. Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev. Neurol. (Paris) 2020 doi: 10.1016/j.neurol.2020.10.001.
    1. Baldini T, et al. Cerebral venous thrombosis and SARS-CoV-2 infection: A systematic review and meta-analysis. Eur. J. Neurol. 2021 doi: 10.1111/ene.14727.
    1. Rogers JP, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611–627. doi: 10.1016/S2215-0366(20)30203-0.
    1. Bacaro V, et al. Insomnia in the Italian population during Covid-19 outbreak: A snapshot on one major risk factor for depression and anxiety. Front. Psychiatry. 2020;11:579107. doi: 10.3389/fpsyt.2020.579107.
    1. Mieczkowska K, et al. Telogen effluvium: A sequela of COVID-19. Int. J. Dermatol. 2021;60:122–124. doi: 10.1111/ijd.15313.
    1. Zhao YM, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.
    1. Ng CK, et al. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax. 2004;59:889–891. doi: 10.1136/thx.2004.023762.
    1. Wang Q, Zhang Z, Shi Y, Jiang Y. Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: Radiologic findings. Radiology. 2013;268:882–889. doi: 10.1148/radiol.13130988.
    1. Huang Y, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir. Res. 2020;21:163. doi: 10.1186/s12931-020-01429-6.
    1. Hui DS, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–409. doi: 10.1136/thx.2004.030205.
    1. Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: What decides the outcome? Nat. Rev. Immunol. 2010;10:514–526. doi: 10.1038/nri2802.
    1. Goertz YMJ, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res. 2020 doi: 10.1183/23120541.00542-2020.
    1. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–474. doi: 10.1126/science.abb8925.
    1. Ngai JC, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15:543–550. doi: 10.1111/j.1440-1843.2010.01720.x.
    1. Suliman YA, et al. Brief report: Pulmonary function tests: High rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol. 2015;67:3256–3261. doi: 10.1002/art.39405.
    1. Del Rio C, Malani PN. COVID-19-new insights on a rapidly changing epidemic. JAMA. 2020;323:1339–1340. doi: 10.1001/jama.2020.3072.
    1. Jason L, Benton M, Torres-Harding S, Muldowney K. The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS. Patient Educ. Couns. 2009;77:237–241. doi: 10.1016/j.pec.2009.02.015.
    1. White PD, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. Lancet. 2011;377:823–836. doi: 10.1016/S0140-6736(11)60096-2.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅